<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Schizophr Res Cogn</journal-id><journal-id journal-id-type="iso-abbrev">Schizophr Res Cogn</journal-id><journal-title-group><journal-title>Schizophrenia Research: Cognition</journal-title></journal-title-group><issn pub-type="epub">2215-0013</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">PMC9440062</article-id><article-id pub-id-type="pii">S2215-0013(22)00034-8</article-id><article-id pub-id-type="doi">10.1016/j.scog.2022.100269</article-id><article-id pub-id-type="publisher-id">100269</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title><italic>Toxoplasma gondii</italic> seropositivity and cognitive function in adults with schizophrenia</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0005"><name><surname>Veleva</surname><given-names>Ivanka</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0010"><name><surname>Stoychev</surname><given-names>Kaloyan</given-names></name><email>kaloyan_stoichev@abv.bg</email><xref rid="af0005" ref-type="aff">a</xref><xref rid="cr0005" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author" id="au0015"><name><surname>Stoimenova-Popova</surname><given-names>Maya</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0020"><name><surname>Stoyanov</surname><given-names>Lyudmil</given-names></name><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0025"><name><surname>Mineva-Dimitrova</surname><given-names>Eleonora</given-names></name><xref rid="af0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0030"><name><surname>Angelov</surname><given-names>Ivelin</given-names></name><xref rid="af0010" ref-type="aff">b</xref></contrib><aff id="af0005"><label>a</label>Department of Psychiatry and Medical Psychology, Medical University Pleven, Bulgaria</aff><aff id="af0010"><label>b</label>Department of Infectious Diseases, Epidemiology, Parasitology and Tropical Medicine, Medical University Pleven, Bulgaria</aff><aff id="af0015"><label>c</label>Department of Public Health Sciences, Medical University Pleven, Bulgaria</aff></contrib-group><author-notes><corresp id="cr0005"><label>&#x0204e;</label>Corresponding author. <email>kaloyan_stoichev@abv.bg</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>27</day><month>8</month><year>2022</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>12</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2022</year></pub-date><volume>30</volume><elocation-id>100269</elocation-id><history><date date-type="received"><day>13</day><month>6</month><year>2022</year></date><date date-type="rev-recd"><day>22</day><month>8</month><year>2022</year></date><date date-type="accepted"><day>22</day><month>8</month><year>2022</year></date></history><permissions><copyright-statement>&#x000a9; 2022 The Authors</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="ab0005"><sec><title>Introduction and methods</title><p>Based on the limited research focusing on the severity of cognitive deterioration in schizophrenia with preceding toxoplasmosis, we sampled 89 demographically matched paranoid schizophrenia patients (mean age 38.97&#x000a0;years) with (n&#x000a0;=&#x000a0;42) and without (n&#x000a0;=&#x000a0;47) seroprevalence of IgG type anti <italic>T. gondii</italic> antibodies as marker of past infection. They underwent examination of verbal memory (10 words Luria test), logical memory and visual memory (BVRT), processing speed (TMT-A/DSST) and executive functions (TMT-B/verbal fluency). We compared the results of both groups, taking into account the normative values for the Bulgarian population where available. We also compared the two groups in terms of clinical severity as evidenced by positive, negative and disorganization sub-scores of the PANSS.</p></sec><sec><title>Results</title><p>While both groups were expectedly under the population norms for verbal and logical memory, seropositive patients showed significantly bigger impairment in verbal memory (Luria Smax&#x000a0;=&#x000a0;72.85 vs 78.51; p&#x000a0;=&#x000a0;0.029), psychomotor speed (TMT-A 50.98&#x000a0;s vs 44.64&#x000a0;s; p&#x000a0;=&#x000a0;0.017), semantic verbal fluency (27.12 vs 30.02; p&#x000a0;=&#x000a0;0.011) and literal verbal fluency (17.17 vs 18.78; p&#x000a0;=&#x000a0;0.014) compared to the seronegative ones. In addition to that, they gave less correct answers on the BVRT (2.98 vs 4.09; p&#x000a0;=&#x000a0;0.006) while making markedly more errors (13.95 vs 10.21; p&#x000a0;=&#x000a0;0.002). Despite not reaching statistical significance, past toxoplasmosis was associated with higher score on the PANSS disorganization sub-scale (16.50 points vs 14.72 points) and with lower educational attainment.</p></sec><sec><title>Conclusion</title><p>Our results suggest a more profound neuropathological insult(s) resulting in greater cognitive impairment in schizophrenia cases that are exposed to <italic>T. gondii</italic> infection.</p></sec></abstract><kwd-group id="ks0005"><title>Keywords</title><kwd>Schizophrenia</kwd><kwd>Toxoplasmosis</kwd><kwd>Cognitive functions</kwd><kwd>Impairment</kwd></kwd-group></article-meta></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p id="p0005">Schizophrenia is a neurodevelopmental disorder that starts prenatally and evolves in early life driven by a combination of genetic and environmental causal factors (<xref rid="bb0050" ref-type="bibr">Degenhardt, 2020</xref>). The pathological process results in structural disorganization of critical brain areas with corresponding disturbances in neurotransmission (<xref rid="bb0035" ref-type="bibr">Callicott et al., 1999</xref>), neuronal connectivity and activation (<xref rid="bb0135" ref-type="bibr">Lewis and Levitt, 2002</xref>; <xref rid="bb0140" ref-type="bibr">Marenco and Weinberger, 2000</xref>). Among the clinical implications of these changes, there is a specific pattern of neurocognitive impairment with ineffective temporo-spatial assessment of incoming information which prevents patients from proper judgments and planning of behavior (<xref rid="bb0240" ref-type="bibr">Veleva et al., 2019</xref>).</p><p id="p0010">Despite the major role of heritability accounting for 60&#x02013;80&#x000a0;% of the overall risk (<xref rid="bb0190" ref-type="bibr">Pettersson et al., 2019</xref>; <xref rid="bb0260" ref-type="bibr">Wray and Gottesman, 2012</xref>), additional environmental factors that interact with genes and trigger the illness are presumably involved. Infections and immune response disorders during the pre and postnatal period have emerged as plausible candidates for this role. Among them, the neurotrophic parasite <italic>Toxoplasma gondii</italic> seems particularly appropriate because it damages neurons directly, affects neurotransmitter systems, and can form cysts in the brain tissue (<xref rid="bb0170" ref-type="bibr">Ortiz-Guerrero et al., 2020</xref>; <xref rid="bb0040" ref-type="bibr">Cetinkaya et al., 2007</xref>; <xref rid="bb0065" ref-type="bibr">Fuglewicz et al., 2017</xref>). Furthermore, <italic>Toxoplasma</italic> IgG seropositivity is 50&#x000a0;% more common among schizophrenia patients compared to controls and it increases the odds of schizophrenia by 1.91-fold (<xref rid="bb0045" ref-type="bibr">Contopoulos-Ioannidis et al., 2022</xref>). Although the association between toxoplasmosis and schizophrenia has been established since the 1950s (<xref rid="bb0125" ref-type="bibr">Kozar, 1953</xref>), the precise neuropathological mechanism(s) that bridges both illnesses remain elusive. The infection induced low-grade inflammation process (<xref rid="bb0065" ref-type="bibr">Fuglewicz et al., 2017</xref>) and the effect of the parasite on the tryptophan-kynurenine pathway are the most popular explanations (<xref rid="bb0230" ref-type="bibr">Tutakhail et al., 2020</xref>; <xref rid="bb0090" ref-type="bibr">Grada et al., 2022</xref>). By activation of astrocytes, <italic>T. gondii</italic> infection increases the brain production of kynurenic acid (KYNA) from tryptophan. Elevated concentration of KYNA alters the glutamatergic, cholinergic, and dopaminergic signaling (<xref rid="bb0210" ref-type="bibr">Stone, 1993</xref>), thus playing important pathogenic role especially for cognitive symptoms (<xref rid="bb0225" ref-type="bibr">Torrey and Yolken, 2003</xref>; <xref rid="bb0200" ref-type="bibr">Schwarcz and Hunter, 2007</xref>; <xref rid="bb0025" ref-type="bibr">Brown et al., 2009</xref>; <xref rid="bb0020" ref-type="bibr">Brown, 2012</xref>; <xref rid="bb0180" ref-type="bibr">Pearce et al., 2020</xref>; <xref rid="bb0185" ref-type="bibr">Pedraz-Petrozzi et al., 2020</xref>). In addition to that, the accumulation of tryptophan degradation products leads to excessive dopaminergic activity which is considered the pathophysiological essence of schizophrenia (<xref rid="bb0150" ref-type="bibr">Miller et al., 2004</xref>).</p><p id="p0015">A number of studies have addressed the association between the seroprevalence of <italic>T. gondii</italic> antibodies and the impairment of cognitive function in mentally healthy individuals. Most (<xref rid="bb0145" ref-type="bibr">Mendy et al., 2015</xref>; <xref rid="bb0080" ref-type="bibr">Gale et al., 2015</xref>; <xref rid="bb0075" ref-type="bibr">Gajewski et al., 2014</xref>; <xref rid="bb0175" ref-type="bibr">Pearce et al., 2014</xref>; <xref rid="bb0010" ref-type="bibr">Beste et al., 2014</xref>; <xref rid="bb0155" ref-type="bibr">Nimgaonkar et al., 2016</xref>; <xref rid="bb0195" ref-type="bibr">Rossini et al., 2019</xref>; <xref rid="bb0085" ref-type="bibr">Gale et al., 2020</xref>) but not all (<xref rid="bb0095" ref-type="bibr">Guenter et al., 2012</xref>; <xref rid="bb0215" ref-type="bibr">Sugden et al., 2016</xref>; <xref rid="bb0220" ref-type="bibr">Torniainen-Holm et al., 2019</xref>) of them find an adverse association between toxoplasmosis and cognitive functioning. In contrast to that, only one study has examined the cognitive performance in schizophrenia patients born to <italic>T. gondii</italic> seropositive mothers (<xref rid="bb0025" ref-type="bibr">Brown et al., 2009</xref>).</p><p id="p0020">Against this background, we examined a sample of individuals with paranoid schizophrenia (PS) divided according to the seroprevalence of IgG type anti-toxoplasma antibodies as a marker of past infection. Our goal was to analyze the results of neuropsychological tests of seropositive and seronegative subjects looking for an association between the level of cognitive performance and the serological status. Additionally, for some of the tests, we compared the performance of the two groups against the norm for the Bulgarian population.</p></sec><sec id="s0010"><label>2</label><title>Materials and methods</title><sec id="s0015"><label>2.1</label><title>Sample</title><p id="p0025">The study included 89 participants (55 males) treated at the Department of Psychiatry of &#x0201c;Dr Georgi Stranski&#x0201d; University Hospital in Pleven, Bulgaria between 2017 and 2018. The subjects were divided into two groups: 42 patients seropositive for anti-toxoplasma IgG antibodies constituted the <italic>T. gondii</italic> positive group (<italic>TG+</italic>), whereas 47 patients lacking such antibodies composed the <italic>T. gondii</italic> negative group (<italic>TG&#x02212;</italic>). Both groups were matched by age, educational level, family history for schizophrenia, mean illness duration and mean antipsychotic dose (<xref rid="t0005" ref-type="table">Table 1</xref>).<table-wrap position="float" id="t0005"><label>Table 1</label><caption><p>Sociodemographic and clinical characteristic of the two groups of PS patients.</p></caption><alt-text id="al0005">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Characteristic</th><th><italic>T. gondii</italic> IgG &#x0201c;+&#x0201d; (n&#x000a0;=&#x000a0;42)</th><th><italic>T. gondii</italic> IgG &#x0201c;&#x02212;&#x0201d; (n&#x000a0;=&#x000a0;47)</th><th>Total</th><th>p value</th></tr></thead><tbody><tr><td>Gender</td><td/><td/><td/><td align="char">0.086</td></tr><tr><td>&#x000a0;- Females</td><td>12 (28.6&#x000a0;%)</td><td>22 (46.8&#x000a0;%)</td><td>34 (38.2&#x000a0;%)</td><td/></tr><tr><td>&#x000a0;- Males</td><td>30 (71.4&#x000a0;%)</td><td>25 (53.2&#x000a0;%)</td><td>55 (61.8&#x000a0;%)</td><td/></tr><tr><td>Age (years&#x000a0;+&#x000a0;SD)</td><td>39.74&#x000a0;&#x000b1;&#x000a0;6.826</td><td>38.28&#x000a0;&#x000b1;&#x000a0;8.665</td><td>38.97&#x000a0;&#x000b1;&#x000a0;7.841</td><td align="char">0.191</td></tr><tr><td>&#x000a0;- Males</td><td>39.53&#x000a0;&#x000b1;&#x000a0;6.806</td><td>38.08&#x000a0;&#x000b1;&#x000a0;8.775</td><td>38.87&#x000a0;&#x000b1;&#x000a0;7.722</td><td/></tr><tr><td>&#x000a0;- Females</td><td>40.25&#x000a0;&#x000b1;&#x000a0;7.149</td><td>38.50&#x000a0;&#x000b1;&#x000a0;8.738</td><td>39.12&#x000a0;&#x000b1;&#x000a0;8.146</td><td/></tr><tr><td>Education</td><td/><td/><td/><td align="char">0.062</td></tr><tr><td>&#x000a0;- Primary or high-school graduates</td><td>34 (81.0&#x000a0;%)</td><td>29 (61.7&#x000a0;%)</td><td>63 (70.8&#x000a0;%)</td><td/></tr><tr><td>&#x000a0;- College graduates or higher</td><td>8 (19.0&#x000a0;%)</td><td>18 (38.3&#x000a0;%)</td><td>26 (29.2&#x000a0;%)</td><td/></tr><tr><td>Family history for schizophrenia</td><td/><td/><td/><td align="char">0.901</td></tr><tr><td>&#x000a0;- Family history positive</td><td>22 (52.4&#x000a0;%)</td><td>24 (51.1&#x000a0;%)</td><td>46 (51.7&#x000a0;%)</td><td/></tr><tr><td>&#x000a0;- Family history negative</td><td>20 (47.6&#x000a0;%)</td><td>23 (48.9&#x000a0;%)</td><td>43 (48.3&#x000a0;%)</td><td/></tr><tr><td>Duration of schizophrenia (years&#x000a0;+&#x000a0;SD)</td><td>13.07&#x000a0;&#x000b1;&#x000a0;5.989</td><td>12.15&#x000a0;&#x000b1;&#x000a0;7.675</td><td>12.58&#x000a0;&#x000b1;&#x000a0;6.908</td><td align="char">0.275</td></tr><tr><td>Antipsychotic dose<xref rid="tf0005" ref-type="table-fn">a</xref> (mg&#x000a0;+&#x000a0;SD)</td><td>302&#x000a0;&#x000b1;&#x000a0;118.036</td><td>324&#x000a0;&#x000b1;&#x000a0;131.339</td><td>314&#x000a0;&#x000b1;&#x000a0;125.009</td><td align="char">0.441</td></tr><tr><td>PANSS score</td><td>73.21&#x000a0;&#x000b1;&#x000a0;7.751</td><td>70.04&#x000a0;&#x000b1;&#x000a0;7.348</td><td>71.54&#x000a0;&#x000b1;&#x000a0;7.665</td><td align="char">0.072</td></tr><tr><td>&#x000a0;- Positive<xref rid="tf0010" ref-type="table-fn">b</xref></td><td>14.19&#x000a0;&#x000b1;&#x000a0;3.704</td><td>13.57&#x000a0;&#x000b1;&#x000a0;3.549</td><td>13.87&#x000a0;&#x000b1;&#x000a0;3.616</td><td align="char">0.473</td></tr><tr><td>&#x000a0;- Negative<xref rid="tf0015" ref-type="table-fn">c</xref></td><td>14.49&#x000a0;&#x000b1;&#x000a0;4.026</td><td>14.22&#x000a0;&#x000b1;&#x000a0;4.315</td><td>14.34&#x000a0;&#x000b1;&#x000a0;4.159</td><td align="char">0.969</td></tr><tr><td>&#x000a0;- Disorganization<xref rid="tf0020" ref-type="table-fn">d</xref></td><td>16.50&#x000a0;&#x000b1;&#x000a0;3.846</td><td>14.72&#x000a0;&#x000b1;&#x000a0;4.557</td><td>15.56&#x000a0;&#x000b1;&#x000a0;4.306</td><td align="char">0.035</td></tr></tbody></table><table-wrap-foot><fn id="tf0005"><label>a</label><p id="np0005">Mean antipsychotic dose has been calculated as a chlorpromazine equivalent.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0010"><label>b</label><p id="np0010">Positive sub-score of the PANSS includes items P1, P3, P5, P6, G1, G9.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0015"><label>c</label><p id="np0015">Negative sub-score of the PANSS includes items N1, N2, N3, N4, N6, G7, G16.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0020"><label>d</label><p id="np0020">Disorganization sub-score of the PANSS includes items P2, N5, N7, G5, G10, G11, G12, G13, G15.</p></fn></table-wrap-foot></table-wrap></p><p id="p0030">All participants were capable adults who had signed informed consent prior to performing any study related procedures. They were fluent in Bulgarian language and had at least eight years of schooling. In addition, all of them were right-handed as assessed by the Edinburgh Handedness Inventory &#x02013; Short Form (<xref rid="bb0235" ref-type="bibr">Veale, 2014</xref>).</p><p id="p0035">The study was approved by the Research Ethics Committee of the Medical University of Pleven. All procedures were performed in accordance with the Declaration of Helsinki (<xref rid="bb0255" ref-type="bibr">World Medical Association Declaration of Helsinki, 2001</xref>).</p><p id="p0040">Participants fulfilled the following inclusion criteria: [1] Diagnosis of PS based on the ICD-10 (<xref rid="bb0250" ref-type="bibr">World Health Organization, 2016</xref>); [2] ongoing therapy with a second-generation antipsychotic that has produced a stable condition as defined by a lack of serious relapse (a change of &#x02265;25&#x000a0;% of the total PANSS score) in the three months preceding study entry; [3] presence of clinically significant positive, negative and/or disorganization symptoms defined by a score of at least &#x0201c;mild&#x0201d; on minimum two of the corresponding PANSS items according to the five factor model of <xref rid="bb0070" ref-type="bibr">van der Gaag et al. (2006)</xref>. Exclusion criteria were: [1] Lifetime history for any other psychiatric condition or history for substance use disorder(s) in the past 12&#x000a0;months; [2] any neurological condition and/or physical illness/impairment that interferes with the proper execution of study procedures.</p><p id="p0045">The ELISA method was used to test for specific anti-toxoplasma antibodies. We employed NovaTec&#x000ae; <italic>Toxoplasma</italic> IgG and NovaTec&#x000ae; <italic>Toxoplasma</italic> IgM diagnostic kits (Immunodiagnostica, Germany). All participants positive for IgG anti-toxoplasma antibodies were also tested for IgM antibodies to rule out acute toxoplasmosis. The quantity of anti-toxoplasma antibodies was measured using an automatic ELISA plate reader with a wavelength range 420&#x02013;650&#x000a0;nm. The results as measured in international units per milliliter were interpreted as follows: <italic>T. gondii</italic> IgG antibodies &#x0003c;30&#x000a0;IU/ml&#x000a0;=&#x000a0;negative result; 30&#x02013;35&#x000a0;IU/ml&#x000a0;=&#x000a0;borderline result; &#x0003e;35&#x000a0;IU/ml&#x000a0;=&#x000a0;positive result. IgM antibodies were measured in NovaTec&#x000ae; units (NTU) with positive result defined as 11 NTU or higher.</p><p id="p0050">All the patients underwent complete physical and psychiatric examination supplemented by medical and family psychiatric history. Neuropsychological examination was performed after an antipsychotic free period of at least 12&#x000a0;h. The following tools were used in the specified order:<list list-type="simple" id="l0005"><list-item id="li0005"><label>-</label><p id="p0055"><bold>10 Words Luria Test:</bold> a verbal memory (VM) test measuring fixation (immediate recall), retention and reproduction (delayed recall) of a list of words. The first five repetitions follow one after the other and test fixation, while delayed repetition (after 1&#x000a0;h) tests for reproduction/delayed recall. Retention is tested by the number of repeated words after a final sixth reading, performed shortly after the reproduction test. Intrusions, i.e. reproducing words that are not part of the set are also noted. Results are calculated by means of formula to produce % value of the mean fixation success rate (S<sub>mf</sub>), maximal fixation (S<sub>max</sub>), retention success rate (S<sub>ret</sub>) and reproduction success rate (S<sub>rep</sub>). For Bulgarians the values of S<sub>mf</sub>, S<sub>max</sub>, S<sub>ret</sub> and S<sub>rep</sub> are interpreted as follows: &#x02265;84&#x000a0;%&#x000a0;=&#x000a0;no deficit; 68&#x000a0;%&#x02013;84&#x000a0;%&#x000a0;=&#x000a0;mild deficit; 51&#x000a0;%&#x02013;68&#x000a0;%&#x000a0;=&#x000a0;moderate deficit; 51&#x000a0;%&#x02013;34&#x000a0;%&#x000a0;=&#x000a0;substantial deficit; &#x0003c;34&#x000a0;%&#x000a0;=&#x000a0;severe deficit</p></list-item><list-item id="li0010"><label>-</label><p id="p0060"><bold>Trail Making Test parts A &#x00026; B (TMT A&#x00026;B)</bold> is a standardized test for assessment of processing speed, attention switching, cognitive flexibility, distributed and selective attention, as well as the ability to form concepts. In addition to that, part B of the test (TMT-B) assesses executive functions.</p></list-item><list-item id="li0015"><label>-</label><p id="p0065">The <bold>Logical Memory Test</bold> measures episodic memory and thinking disorders and consists of memorizing and reproducing two short stories (LM1 and LM2) that are read to the participant. Each of the stories contains 24 elements (N1-N24). Results are presented in % by means of the formula N&#x000a0;&#x000d7;&#x000a0;100&#x000a0;/&#x000a0;24. Their interpretation is the same as in the Luria test.</p></list-item><list-item id="li0020"><label>-</label><p id="p0070"><bold>Digit Symbol Substitution Test (DSST)</bold> is a sub-part of the Wechsler Adult Intelligence Scale (WAIS) designed to measure visuo-perceptual functions, attention, executive functions (including working memory) and motor speed (<xref rid="bb0105" ref-type="bibr">Jaeger, 2018</xref>).</p></list-item><list-item id="li0025"><label>-</label><p id="p0075"><bold>Verbal fluency test (VF)</bold> grades executive functions and semantic memory. Lower VF scores indicate deficit in processing of semantic information. VF is subdivided into semantic VF (VF<sub>s</sub>) measured by Isaac's Set Test (IST) (Bulgarian norm &#x0003e;30&#x000a0;words/min) and literal VF (VF<sub>l</sub>) assessed by the number of words beginning with a certain letter that can be produced in 60&#x000a0;s (Bulgarian norm &#x0003e;20 words)</p></list-item><list-item id="li0030"><label>-</label><p id="p0080"><bold>Benton Visual Retention Test (BVRT)</bold> is a tool developed to assess visual perception, visual memory, and basic visual abilities, visuo-motor coordination and perceptual-motor integration. For the Bulgarian population the mean value of correct scores is 8.20 and the normal mean number of errors is 5.5.</p></list-item></list></p></sec><sec id="s0020"><label>2.2</label><title>Statistics</title><p id="p0085">Analysis was performed via descriptive and correlation statistical techniques. Demographic and clinical characteristics of <italic>TG+</italic> and <italic>TG&#x02212;</italic> patients were compared using One-tailed <italic>t</italic>-test for independent samples (for normal distribution), Mann-Whitney <italic>U</italic> test (for asymmetrical distribution) and chi-squared tests for categorical data. We used the Cohen's D method and Cramer's V to compute the intensity of the relationship between groups or sets of variable effect size. Calculations were made by SPSS v.28.0 for Windows based PCs. All results were processed within a 95&#x000a0;% confidence interval.</p></sec></sec><sec id="s0025"><label>3</label><title>Results</title><sec id="s0030"><label>3.1</label><title>Associations between the serological status and the clinical and socio-demographic characteristics</title><p id="p0090">To test for association between the serological status and the age of onset of schizophrenia, we calculated correlation coefficient Eta. The difference between the two groups was not statistically significant (U&#x000a0;=&#x000a0;975.500, N&#x000a0;=&#x000a0;89, z&#x000a0;=&#x000a0;0.095, d&#x000a0;=&#x000a0;0.02, p&#x000a0;&#x0003e;&#x000a0;0.05), i.e. seropositivity was not associated with earlier or later age of onset of the mental disease (&#x003b7;&#x000a0;=&#x000a0;0.042, N&#x000a0;=&#x000a0;89).</p><p id="p0095">With respect to the overall clinical severity, both groups did not differ significantly in the total, positive and negative PANSS score (<xref rid="t0005" ref-type="table">Table 1</xref>). However, disorganization symptoms sub-score did show significantly higher value in the <italic>TG+</italic> group under one-tailed test (t&#x000a0;=&#x000a0;767.500, N&#x000a0;=&#x000a0;87, d&#x000a0;=&#x000a0;0.42, p&#x000a0;=&#x000a0;0.035).</p><p id="p0100">We did not find association between the serological status and the level of education (&#x003c7;<sup>2</sup>(2)&#x000a0;=&#x000a0;4.491, p&#x000a0;&#x0003e;&#x000a0;0.05, Cramer's V&#x000a0;=&#x000a0;0.225). However, &#x0003c;20&#x000a0;% of <italic>TG+</italic> patients had college degree or higher educational attainment vs nearly 40&#x000a0;% in the <italic>TG&#x02212;</italic> group &#x02013; a finding that suggests higher educational achievement of the latter.</p></sec><sec id="s0035"><label>3.2</label><title>Associations between the serological status and the performance on neurocognitive tests</title><p id="p0105">
<list list-type="simple" id="l0010"><list-item id="li0035"><p id="p0110"><bold>Verbal memory:</bold> according to the Bulgarian norm, patients from both groups had a moderate decrease in S<sub>mf</sub>, mild deficit in S<sub>max</sub> and in S<sub>rep</sub>, and moderate deficit in S<sub>ret</sub>. Seropositive patients had lower S<sub>mf</sub> and S<sub>ret</sub> and significantly lower S<sub>max</sub> results compared to seronegative ones, while the difference in reproduction and number of intrusions between the two groups was negligible.</p></list-item><list-item id="li0040"><p id="p0115"><bold>Logical memory:</bold> Both groups had severe impairment against the population norm with <italic>TG+</italic> patients performing insignificantly worse than <italic>TG&#x02212;</italic> ones.</p></list-item><list-item id="li0045"><p id="p0120"><bold>Visual memory (BVRT):</bold> in this task, <italic>TG&#x02212;</italic> patients gave significantly more correct answers (U&#x000a0;=&#x000a0;657.500, N&#x000a0;=&#x000a0;89, z&#x000a0;=&#x000a0;&#x02212;2.740, d&#x000a0;=&#x000a0;0.60, p&#x000a0;=&#x000a0;0.006) and made significantly less errors (U&#x000a0;=&#x000a0;609.500, N&#x000a0;=&#x000a0;89, z&#x000a0;=&#x000a0;3.111, d&#x000a0;=&#x000a0;0.70, p&#x000a0;=&#x000a0;0.002) compared to <italic>TG+</italic> ones. However, there was not significant difference in the type of errors (p&#x000a0;&#x0003e;&#x000a0;0.05). Besides, both groups gave less correct answers and made more errors compared to the population norm.</p></list-item><list-item id="li0050"><p id="p0125"><bold>Processing speed (&#x00422;&#x0041c;&#x00422;-&#x00410;/DSST):</bold> Seronegative patients performed significantly better than seropositive ones in terms of processing speed as measured by the TMT-A (U&#x000a0;=&#x000a0;696.500, N&#x000a0;=&#x000a0;89, z&#x000a0;=&#x000a0;2.390, d&#x000a0;=&#x000a0;0.52, p&#x000a0;=&#x000a0;0.017). DSST performance was also in favor of <italic>TG&#x02212;</italic> patients, albeit the difference was not so substantial (35.70 vs 32.62 points).</p></list-item><list-item id="li0055"><p id="p0130"><bold>Executive functions (TMT-B):</bold> seropositive patients needed more time to complete this test compared to seronegative ones (115.0&#x000a0;s vs 101.34&#x000a0;s) although this difference was not statistically significant.</p></list-item><list-item id="li0060"><p id="p0135"><bold>Verbal fluency:</bold> with educational level taken into account, both <italic>TG+</italic> and <italic>TG&#x02212;</italic> groups' mean VF<sub>s</sub> and VF<sub>l</sub> results were below the population norms. Compared to the seropositive patients, seronegative ones had significantly better result for both VF<sub>s</sub> (t&#x000a0;=&#x000a0;2.326, df&#x000a0;=&#x000a0;87, d&#x000a0;=&#x000a0;0.50, p&#x000a0;=&#x000a0;0.011) and VF<sub>l</sub> (t&#x000a0;=&#x000a0;2.227, df&#x000a0;=&#x000a0;87, d&#x000a0;=&#x000a0;0.48, p&#x000a0;=&#x000a0;0.014).</p></list-item></list>
</p></sec></sec><sec id="s0040"><label>4</label><title>Discussion</title><p id="p0140">The present study compared the cognitive performance of two groups of paranoid schizophrenia patients - one with and the other without past <italic>T. gondii</italic> infection - as evidenced by the presence or absence of IgG toxoplasma antibodies. The results will be briefly reviewed below.</p><p id="p0145">Both seropositive and seronegative patients showed deficit in verbal memory (Luria test), especially in the fixation/registration of new words (immediate recall). This deficit was markedly more pronounced in <italic>TG+</italic> patients. While the worse performance relative to the general population may be explained by the impairment of consolidation of new information typical for schizophrenia (<xref rid="bb0115" ref-type="bibr">Keefe and Harvey, 2012</xref>), the intergroup difference deserves more attention as it replicates previously reported data. Specifically, <xref rid="bb0075" ref-type="bibr">Gajewski et al. (2014)</xref> have found poorer performance in verbal memory affecting both immediate and delayed recall in <italic>T. gondii</italic> seropositive seniors in Germany. As these authors have explored mentally fit individuals, it could be speculated that <italic>T. gondii</italic> infection, even when asymptomatic, may be associated with a specific type of memory deterioration. With respect to the retention and reproduction part of the <italic>Luria</italic> test (measuring delayed recall and hence indicative of long-term semantic memory), both groups performed worse against the norm whereas they did not differ significantly compared to each other (<xref rid="t0010" ref-type="table">Table 2</xref>). While this last finding is in discord with the abovementioned German study which showed substantial advantage of <italic>TG</italic>-negative patients in the recall from long-term semantic memory, it should be emphasized that Gajewski et al. have measured this component based on the Word-Fluency-Test. When the results from the same test in our study are taken into account, the difference between the two groups becomes visible, i.e. <italic>T. gondii</italic> negative patients perform significantly better (mean 30.56 vs 26.55, U&#x000a0;=&#x000a0;910, Z&#x000a0;=&#x000a0;-3.369, p&#x000a0;=&#x000a0;0.001). A separate comment requires the significant impairment in retention seen in both samples. This finding contradicts the prevailing view for larger deficits in learning than in retention in schizophrenia (<xref rid="bb0115" ref-type="bibr">Keefe and Harvey, 2012</xref>). While the small size of our sample could account for it, this result nevertheless needs to be emphasized as it complies with a large meta-analysis (<xref rid="bb0060" ref-type="bibr">Fioravanti et al., 2012</xref>) reporting substantial heterogeneity in the results of studies exploring memory functioning in schizophrenia.<table-wrap position="float" id="t0010"><label>Table 2</label><caption><p>Results of the neurocognitive test battery in TG+ and TG&#x02212; patients.</p></caption><alt-text id="al0010">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Parameter/test</th><th>Seronegative (TG&#x02212;)</th><th>Seropositive (TG+)</th><th>Mann-Whitney U/<italic>t</italic>-test</th><th>Asymp. sig. (2-tailed)</th></tr></thead><tbody><tr><td colspan="5"><italic>10 Words Luria Test</italic></td></tr><tr><td>S<sub>mf</sub></td><td>66.21&#x000a0;&#x000b1;&#x000a0;13.143</td><td>61.76&#x000a0;&#x000b1;&#x000a0;14.994</td><td>778.000</td><td align="char">0.085</td></tr><tr><td>S<sub>max</sub></td><td>78.51&#x000a0;&#x000b1;&#x000a0;12.850</td><td>72.85&#x000a0;&#x000b1;&#x000a0;14.863</td><td>728.000</td><td align="char"><bold><italic>0.029</italic></bold></td></tr><tr><td>S<sub>rep</sub></td><td>74.92&#x000a0;&#x000b1;&#x000a0;12.549</td><td>74.46&#x000a0;&#x000b1;&#x000a0;14.494</td><td>962.000</td><td align="char">0.839</td></tr><tr><td>S<sub>ret</sub></td><td>58.94&#x000a0;&#x000b1;&#x000a0;13.868</td><td>55.24&#x000a0;&#x000b1;&#x000a0;14.523</td><td>834.000</td><td align="char">0.200</td></tr><tr><td>Intrusions</td><td>0.62&#x000a0;&#x000b1;&#x000a0;0.922</td><td>0.83&#x000a0;&#x000b1;&#x000a0;1.167</td><td>922.000</td><td align="char">0.544</td></tr><tr><td colspan="5">&#x02028;&#x02028;</td></tr><tr><td colspan="5"><italic>Logical memory test</italic></td></tr><tr><td>LM-1</td><td>32.17&#x000a0;&#x000b1;&#x000a0;12.487</td><td>30.58&#x000a0;&#x000b1;&#x000a0;14.604</td><td>867.000</td><td align="char">0.324</td></tr><tr><td>LM-2</td><td>25.70&#x000a0;&#x000b1;&#x000a0;13.460</td><td>22.11&#x000a0;&#x000b1;&#x000a0;12.012</td><td>775.000</td><td align="char">0.078</td></tr><tr><td colspan="5">&#x02028;&#x02028;</td></tr><tr><td colspan="5"><italic>Benton Visual Retention Test</italic></td></tr><tr><td>BVRT-correct</td><td>4.09&#x000a0;&#x000b1;&#x000a0;1.730</td><td>2.98&#x000a0;&#x000b1;&#x000a0;1.944</td><td>657.500</td><td align="char"><bold><italic>0.006</italic></bold></td></tr><tr><td>BVRT-error</td><td>10.21&#x000a0;&#x000b1;&#x000a0;4.383</td><td>13.950&#x000a0;&#x000b1;&#x000a0;6.052</td><td>609.500</td><td align="char"><bold><italic>0.002</italic></bold></td></tr><tr><td colspan="5">&#x02028;&#x02028;</td></tr><tr><td colspan="5"><italic>Digit Symbol Substitution Test</italic></td></tr><tr><td>DSST</td><td>35.70&#x000a0;&#x000b1;&#x000a0;10.885</td><td>32.62&#x000a0;&#x000b1;&#x000a0;9.197</td><td>826.000</td><td>0.187</td></tr><tr><td colspan="5">&#x02028;&#x02028;</td></tr><tr><td colspan="5"><italic>Trail Making Test parts A &#x00026; B</italic></td></tr><tr><td>TMT-A sec</td><td>44.64&#x000a0;&#x000b1;&#x000a0;18.652</td><td>50.98&#x000a0;&#x000b1;&#x000a0;17.506</td><td>696.500</td><td align="char"><bold><italic>0.017</italic></bold></td></tr><tr><td>TMT-B sec</td><td>101.34&#x000a0;&#x000b1;&#x000a0;35.073</td><td>115.00&#x000a0;&#x000b1;&#x000a0;41.282</td><td>824.500</td><td align="char">0.183</td></tr><tr><td colspan="5">&#x02028;&#x02028;</td></tr><tr><td colspan="5"><italic>Verbal fluency test</italic></td></tr><tr><td>VF-s</td><td>30.02&#x000a0;&#x000b1;&#x000a0;6.124</td><td>27.12&#x000a0;&#x000b1;&#x000a0;5.584</td><td>2.326</td><td align="char"><bold><italic>0.011</italic></bold></td></tr><tr><td>VF-l</td><td>18.79&#x000a0;&#x000b1;&#x000a0;3.759</td><td>17.17&#x000a0;&#x000b1;&#x000a0;3.012</td><td>2.227</td><td align="char"><bold><italic>0.014</italic></bold></td></tr></tbody></table><table-wrap-foot><fn id="sp0015"><p><italic>S</italic><sub><italic>mf</italic></sub> - mean fixation success; <italic>S</italic><sub><italic>max</italic></sub> - maximum success; <italic>S</italic><sub><italic>rep</italic></sub> - reproduction success; <italic>S</italic><sub><italic>ret</italic></sub> - retention success; <italic>LM</italic><sub>1</sub> - logical memory first text; <italic>LM</italic><sub>2</sub> - logical memory second test; <italic>VF</italic><sub><italic>s</italic></sub> - semantic verbal fluency; <italic>VF</italic><sub><italic>L</italic></sub> - literal verbal fluency; &#x00422;&#x0041c;&#x00422;-A&#x000a0;=&#x000a0;trail making test &#x00440;&#x00430;rt - A; &#x00422;&#x0041c;&#x00422;-B&#x000a0;=&#x000a0;trail making test &#x00440;&#x00430;rt - &#x00412;; DDST - digit symbol substitution test; <italic>BVRT</italic><sub><italic>correct</italic></sub> - number of correct answers; <italic>BVRT</italic><sub><italic>error</italic></sub> - number of errors.</p></fn><fn id="sp10005"><p>Values in bold-italics are statistically significant.</p></fn></table-wrap-foot></table-wrap></p><p id="p0150">Logical memory was severely deficient in both groups compared to normative results but again, seronegative patients performed better by reproducing more items of the test material. In addition to that, their performance was affected by interreferences to a lesser extent. The likely explanation for the huge difference from normal values as well as between the groups is the disorganization symptoms which were more expressed in <italic>TG+</italic> patients. As shown by at least one previous study (<xref rid="bb0165" ref-type="bibr">O'Leary et al., 2000</xref>), disorganization symptoms correlate with lower verbal IQ results thus implying poorer verbal comprehension. Backing this possibility, a meta-analysis of schizophrenia neurocognition studies (<xref rid="bb0245" ref-type="bibr">Ventura et al., 2010</xref>) has shown that disorganization symptoms are related to a more severe impairment across all cognitive domains including verbal memory.</p><p id="p0155">Visual memory was more impaired in <italic>TG+</italic> patients as they had significantly more errors and less correct answers in the BVRT in which neither of the two groups reached population norms. Insofar as the performance on visual memory tests closely correlates with executive function (<xref rid="bb0160" ref-type="bibr">Obayashi et al., 2003</xref>; <xref rid="bb0120" ref-type="bibr">Kim et al., 2008</xref>), these results are indicative of more severe deterioration in this cognitive domain in <italic>TG+</italic> patients as opposed to <italic>TG&#x02212;</italic> ones. Further support for such an inference was the results of TMT-A and B tests. As shown on <xref rid="t0010" ref-type="table">Table 2</xref>, they outlined a clear underperformance of <italic>TG+</italic> patients in terms of psychomotor processing speed (TMT-A/DSST) and executive functions (TMT-B).</p><p id="p0160">The greater impairment of executive functions that we observed in <italic>TG+</italic> patients may be explained in several ways. First, it could be a direct consequence of the slower psychomotor processing speed. Supporting such a hypothesis, seropositive patients performed worse on both TMT-A and DSST tests which reflect the overall rate of psychomotor processing (<xref rid="bb0105" ref-type="bibr">Jaeger, 2018</xref>; <xref rid="bb0130" ref-type="bibr">Laere et al., 2018</xref>). It is also possible that the finding reflects a deeper cognitive problem in reasoning and problem-solving - either a deficit in planning the necessary action sequence or a deficit in set-shifting, i.e., the ability to switch mental sets in order to perform a certain task. Finally, it may reflect a more global neurocognitive deficit affecting visual perception, problem-solving, working memory, and processing speed (<xref rid="bb0100" ref-type="bibr">Harvey et al., 2019</xref>). Regardless of its causality, this finding is consistent with studies on schizophrenia patients (<xref rid="bb0025" ref-type="bibr">Brown et al., 2009</xref>), mentally healthy subjects with toxoplasmosis (<xref rid="bb0145" ref-type="bibr">Mendy et al., 2015</xref>; <xref rid="bb0080" ref-type="bibr">Gale et al., 2015</xref>; <xref rid="bb0075" ref-type="bibr">Gajewski et al., 2014</xref>; <xref rid="bb0175" ref-type="bibr">Pearce et al., 2014</xref>; <xref rid="bb0010" ref-type="bibr">Beste et al., 2014</xref>; <xref rid="bb0155" ref-type="bibr">Nimgaonkar et al., 2016</xref>; <xref rid="bb0195" ref-type="bibr">Rossini et al., 2019</xref>; <xref rid="bb0085" ref-type="bibr">Gale et al., 2020</xref>) and animal models (<xref rid="bb0110" ref-type="bibr">Kannan and Pletnikov, 2012</xref>) and supports the assumption that executive functioning may be particularly vulnerable to the effects of pre- and postnatal damages on the developing brain (<xref rid="bb0025" ref-type="bibr">Brown et al., 2009</xref>; <xref rid="bb0110" ref-type="bibr">Kannan and Pletnikov, 2012</xref>).</p><p id="p0165">Finally, regarding verbal fluency assessment, again seronegative patients had statistically significant advantage in both the semantic (VF<sub>s</sub>) and literal (VF<sub>l</sub>) components of these tests. In this respect, our results are in disparity with what has been reported by <xref rid="bb0025" ref-type="bibr">Brown et al. (2009)</xref>. These authors have noticed significant difference between schizophrenia patients that have and have not been exposed to <italic>T. gondii</italic> infection prenatally for VF<sub>s</sub> only and not for VF<sub>l</sub>. A likely reason for this incongruence could be methodological differences (Brown et al. have explored the seroprevalence of <italic>T. gondii</italic> IgG antibodies in mothers and not in patients themselves) as well as sample differences in terms of age, education, social background, illness duration and severity.</p><p id="p0170">Several limitations of the present work need mentioning. First, as a result of the cross-sectional design we employed, the principal question remains of whether the observed cognitive deficit in seropositive patients has occurred after the infection or has predated it. Furthermore, even if we assume that the infection precedes and (possibly) accounts for the greater cognitive deficit, there is the uncertainty of whether <italic>toxoplasmosis</italic> has been congenital or if it was acquired later in life (before or after the onset of schizophrenia). Finally, it should be noted that both cognitive functioning and cognitive tests performance are phenomena with a multifactorial determination, i.e., they are influenced by a range of factors such as genetics (<xref rid="bb0030" ref-type="bibr">Burdick et al., 2013</xref>; <xref rid="bb0265" ref-type="bibr">Zai et al., 2017</xref>), intelligence (<xref rid="bb0015" ref-type="bibr">Bleecker et al., 1988</xref>), individual experience (<xref rid="bb0055" ref-type="bibr">Diamond, 2013</xref>) occupation and education (<xref rid="bb0205" ref-type="bibr">Singh-Manoux et al., 2011</xref>), motivation (<xref rid="bb0005" ref-type="bibr">Beck et al., 2018</xref>), as well as the broader sociocultural environment (<xref rid="bb0055" ref-type="bibr">Diamond, 2013</xref>).</p></sec><sec id="s0045"><label>5</label><title>Conclusion</title><p id="p0175">Our study showed that PS patients seropositive for IgG anti-toxoplasma antibodies have more severe impairment across a range of cognitive domains &#x02013; verbal/visual memory, psychomotor speed and executive functions &#x02013; compared to seronegative PS patients. In addition to that, the seroprevalence of IgG antibodies was associated with higher score on the PANSS disorganization sub-scale and with lower educational attainment. Considering the comparable overall illness severity between the two groups, these results are suggestive of a more profound neuropathological insult(s) in schizophrenia cases in which there is a superimposed <italic>T. gondii</italic> infection. Thus, it may be assumed that the latter alone or in combination with other causal factors acting in the intrauterine period or later in life, could disrupt the process of brain development.</p><p id="p0180">A deeper insight in the neuropathological mechanisms that underlie the greater cognitive impairment in schizophrenia cases that have been exposed to <italic>toxoplasmosis</italic> would potentially enhance our understanding of the etiopathogenesis of both disorders and open up new therapeutic approaches. Hence, future studies similar to the current one but with larger samples and longitudinal design combined with contemporary neurobiological assessments are warranted.</p></sec><sec id="s0050"><title>CRediT authorship contribution statement</title><p id="p0185">All authors of this publication have read and accepted the revised version of the paper.</p></sec></body><back><ref-list id="bi0005"><title>References</title><ref id="bb0005"><element-citation publication-type="journal" id="rf202208230800332919"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>A.T.</given-names></name><name><surname>Himelstein</surname><given-names>R.</given-names></name><name><surname>Bredemeier</surname><given-names>K.</given-names></name><name><surname>Silverstein</surname><given-names>S.M.</given-names></name><name><surname>Grant</surname><given-names>P.</given-names></name></person-group><article-title>What accounts for poor functioning in people with schizophrenia: a re-evaluation of the contributions of neurocognitive v. attitudinal and motivational factors</article-title><source>Psychol. Med.</source><volume>48</volume><issue>16</issue><year>2018</year><fpage>2776</fpage><lpage>2785</lpage><pub-id pub-id-type="doi">10.1017/S0033291718000442</pub-id><pub-id pub-id-type="pmid">29501072</pub-id></element-citation></ref><ref id="bb0010"><element-citation publication-type="journal" id="rf202208230758081501"><person-group person-group-type="author"><name><surname>Beste</surname><given-names>C.</given-names></name><name><surname>Getzmann</surname><given-names>S.</given-names></name><name><surname>Gajewski</surname><given-names>P.D.</given-names></name><name><surname>Golka</surname><given-names>K.</given-names></name><name><surname>Falkenstein</surname><given-names>M.</given-names></name></person-group><article-title>Latent Toxoplasma gondii infection leads to deficits in goal-directed behavior in healthy elderly</article-title><source>Neurobiol. Aging</source><volume>35</volume><issue>5</issue><year>2014</year><fpage>1037</fpage><lpage>1044</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2013.11.012</pub-id><comment>PMID: 24315729</comment><pub-id pub-id-type="pmid">24315729</pub-id></element-citation></ref><ref id="bb0015"><element-citation publication-type="journal" id="rf202208230800188389"><person-group person-group-type="author"><name><surname>Bleecker</surname><given-names>M.L.</given-names></name><name><surname>Bolla-Wilson</surname><given-names>K.</given-names></name><name><surname>Agnew</surname><given-names>J.</given-names></name><name><surname>Meyers</surname><given-names>D.A.</given-names></name></person-group><article-title>Age-related sex differences in verbal memory</article-title><source>J. Clin. Psychol.</source><volume>44</volume><issue>3</issue><year>1988</year><fpage>403</fpage><lpage>411</lpage><pub-id pub-id-type="pmid">3384968</pub-id></element-citation></ref><ref id="bb0020"><element-citation publication-type="journal" id="rf202208230757355502"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>A.S.</given-names></name></person-group><article-title>Epidemiologic studies of exposure to prenatal infection and risk of schizophrenia and autism</article-title><source>Dev. Neurobiol.</source><volume>72</volume><issue>10</issue><year>2012</year><fpage>1272</fpage><lpage>1276</lpage><pub-id pub-id-type="pmid">22488761</pub-id></element-citation></ref><ref id="bb0025"><element-citation publication-type="journal" id="rf202208230745384301"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>A.S.</given-names></name><name><surname>Vinogradov</surname><given-names>S.</given-names></name><name><surname>Kremen</surname><given-names>W.S.</given-names></name><name><surname>Poole</surname><given-names>J.H.</given-names></name><name><surname>Deicken</surname><given-names>R.F.</given-names></name><name><surname>Penner</surname><given-names>J.D.</given-names></name><name><surname>Schaefer</surname><given-names>C.A.</given-names></name><x>&#x02026;</x></person-group><article-title>Prenatal exposure to maternal infection and executive dysfunction in adult schizophrenia</article-title><source>Am. J. Psychiatr.</source><volume>166</volume><issue>6</issue><year>2009</year><fpage>683</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2008.08010089</pub-id><pub-id pub-id-type="pmid">19369317</pub-id></element-citation></ref><ref id="bb0030"><element-citation publication-type="book" id="rf202208230756053044"><person-group person-group-type="author"><name><surname>Burdick</surname><given-names>K.E.</given-names></name><name><surname>Glicksberg</surname><given-names>B.</given-names></name><name><surname>Donohoe</surname><given-names>G.</given-names></name></person-group><part-title>Genetic influences on cognition in schizophrenia</part-title><source>Cognitive Impairment in Schizophrenia: Characteristics, Assessment And Treatment</source><volume>161</volume><year>2013</year></element-citation></ref><ref id="bb0035"><element-citation publication-type="journal" id="rf202208230756281463"><person-group person-group-type="author"><name><surname>Callicott</surname><given-names>J.H.</given-names></name><name><surname>Mattay</surname><given-names>V.S.</given-names></name><name><surname>Bertolino</surname><given-names>A.</given-names></name><name><surname>Finn</surname><given-names>K.</given-names></name><name><surname>Coppola</surname><given-names>R.</given-names></name><name><surname>Frank</surname><given-names>J.A.</given-names></name><name><surname>Weinberger</surname><given-names>D.R.</given-names></name><x>&#x02026;</x></person-group><article-title>Physiological characteristics of capacity constraints in working memory as revealed by functional MRI</article-title><source>Cereb. Cortex</source><volume>9</volume><issue>1</issue><year>1999</year><fpage>20</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">10022492</pub-id></element-citation></ref><ref id="bb0040"><element-citation publication-type="journal" id="rf202208230756494882"><person-group person-group-type="author"><name><surname>Cetinkaya</surname><given-names>Z.</given-names></name><name><surname>Yazar</surname><given-names>S.</given-names></name><name><surname>Gecici</surname><given-names>O.</given-names></name><name><surname>Namli</surname><given-names>M.N.</given-names></name></person-group><article-title>Anti-Toxoplasma gondii antibodies in patients with schizophrenia&#x02014;preliminary findings in a Turkish sample</article-title><source>Schizophr. Bull.</source><volume>33</volume><issue>3</issue><year>2007</year><fpage>789</fpage><lpage>791</lpage><pub-id pub-id-type="pmid">17404388</pub-id></element-citation></ref><ref id="bb0045"><element-citation publication-type="journal" id="rf202208230745284112"><person-group person-group-type="author"><name><surname>Contopoulos-Ioannidis</surname><given-names>D.G.</given-names></name><name><surname>Gianniki</surname><given-names>M.</given-names></name><name><surname>Ai-Nhi Truong</surname><given-names>A.</given-names></name><name><surname>Montoya</surname><given-names>J.G.</given-names></name></person-group><article-title>Toxoplasmosis and schizophrenia: a systematic review and meta-analysis of prevalence and associations and future directions</article-title><source>Psychiatr. Res. Clin. Pract.</source><volume>4</volume><year>2022</year><fpage>48</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1176/appi.prcp.202110041</pub-id></element-citation></ref><ref id="bb0050"><element-citation publication-type="journal" id="rf202208230756231793"><person-group person-group-type="author"><name><surname>Degenhardt</surname><given-names>F.</given-names></name></person-group><article-title>Update on the genetic architecture of schizophrenia</article-title><source>Med. Genet.</source><volume>32</volume><issue>1</issue><year>2020</year><fpage>19</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1515/medgen-2020-2009</pub-id></element-citation></ref><ref id="bb0055"><element-citation publication-type="journal" id="rf202208230800210499"><person-group person-group-type="author"><name><surname>Diamond</surname><given-names>A.</given-names></name></person-group><article-title>Executive functions</article-title><source>Annu. Rev. Psychol.</source><volume>64</volume><year>2013</year><fpage>135</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">23020641</pub-id></element-citation></ref><ref id="bb0060"><element-citation publication-type="journal" id="rf202208230752106342"><person-group person-group-type="author"><name><surname>Fioravanti</surname><given-names>M.</given-names></name><name><surname>Bianchi</surname><given-names>V.</given-names></name><name><surname>Cinti</surname><given-names>M.E.</given-names></name></person-group><article-title>Cognitive deficits in schizophrenia: an updated metanalysis of the scientific evidence</article-title><source>BMC Psychiatry</source><volume>12</volume><issue>1</issue><year>2012</year><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1186/1471-244X-12-64</pub-id><pub-id pub-id-type="pmid">22230388</pub-id></element-citation></ref><ref id="bb0065"><element-citation publication-type="journal" id="rf202208230756525272"><person-group person-group-type="author"><name><surname>Fuglewicz</surname><given-names>A.J.</given-names></name><name><surname>Piotrowski</surname><given-names>P.</given-names></name><name><surname>Stodolak</surname><given-names>A.</given-names></name></person-group><article-title>Relationship between toxoplasmosis and schizophrenia: a review</article-title><source>Adv. Clin. Exp. Med.</source><volume>26</volume><issue>6</issue><year>2017</year><fpage>1031</fpage><lpage>1036</lpage><pub-id pub-id-type="pmid">29068607</pub-id></element-citation></ref><ref id="bb0070"><element-citation publication-type="journal" id="rf202208230751415612"><person-group person-group-type="author"><name><surname>van der Gaag</surname><given-names>M.</given-names></name><name><surname>Cuijpers</surname><given-names>A.</given-names></name><name><surname>Hoffman</surname><given-names>T.</given-names></name><name><surname>Remijsen</surname><given-names>M.</given-names></name><name><surname>Hijman</surname><given-names>R.</given-names></name><name><surname>de Haan</surname><given-names>L.</given-names></name><name><surname>Wiersma</surname><given-names>D.</given-names></name><x>&#x02026;</x></person-group><article-title>The five-factor model of the Positive and Negative Syndrome Scale I: confirmatory factor analysis fails to confirm 25 published five-factor solutions</article-title><source>Schizophr. Res.</source><volume>85</volume><issue>1&#x02013;3</issue><year>2006</year><fpage>273</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2006.03.021</pub-id><comment>Epub 2006 May 26 PMID: 16730429</comment><pub-id pub-id-type="pmid">16730430</pub-id></element-citation></ref><ref id="bb0075"><element-citation publication-type="journal" id="rf202208230757444321"><person-group person-group-type="author"><name><surname>Gajewski</surname><given-names>P.D.</given-names></name><name><surname>Falkenstein</surname><given-names>M.</given-names></name><name><surname>Hengstler</surname><given-names>J.G.</given-names></name><name><surname>Golka</surname><given-names>K.</given-names></name></person-group><article-title>Toxoplasma gondii impairs memory in infected seniors</article-title><source>Brain Behav. Immun.</source><volume>36</volume><year>2014</year><fpage>193</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2013.11.019</pub-id><pub-id pub-id-type="pmid">24321215</pub-id></element-citation></ref><ref id="bb0080"><element-citation publication-type="journal" id="rf202208230745466122"><person-group person-group-type="author"><name><surname>Gale</surname><given-names>S.D.</given-names></name><name><surname>Brown</surname><given-names>B.L.</given-names></name><name><surname>Erickson</surname><given-names>L.D.</given-names></name><name><surname>Berrett</surname><given-names>A.</given-names></name><name><surname>Hedges</surname><given-names>D.W.</given-names></name></person-group><article-title>Association between latent toxoplasmosis and cognition in adults: a cross-sectional study</article-title><source>Parasitology</source><volume>142</volume><issue>4</issue><year>2015</year><fpage>557</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.1017/S0031182014001577</pub-id><comment>PMID: 25377129</comment><pub-id pub-id-type="pmid">25377129</pub-id></element-citation></ref><ref id="bb0085"><element-citation publication-type="journal" id="rf202208230758152651"><person-group person-group-type="author"><name><surname>Gale</surname><given-names>S.D.</given-names></name><name><surname>Erickson</surname><given-names>L.D.</given-names></name><name><surname>Thacker</surname><given-names>E.L.</given-names></name><name><surname>Mitchell</surname><given-names>E.L.</given-names></name><name><surname>Brown</surname><given-names>B.L.</given-names></name><name><surname>Hedges</surname><given-names>D.W.</given-names></name></person-group><article-title>Toxoplasma gondii seropositivity and serointensity and cognitive function in adults</article-title><source>PLoS Negl. Trop. Dis.</source><volume>14</volume><issue>10</issue><year>2020</year><object-id pub-id-type="publisher-id">e0008733</object-id><pub-id pub-id-type="other">10.1371/journal.pntd.0008733 9</pub-id></element-citation></ref><ref id="bb0090"><element-citation publication-type="journal" id="rf202208230757112052"><person-group person-group-type="author"><name><surname>Grada</surname><given-names>S.</given-names></name><name><surname>Mihu</surname><given-names>A.G.</given-names></name><name><surname>Petrescu</surname><given-names>C.</given-names></name><name><surname>Suciu</surname><given-names>O.</given-names></name><name><surname>Marincu</surname><given-names>I.</given-names></name><name><surname>Lupu</surname><given-names>M.A.</given-names></name><name><surname>Olariu</surname><given-names>T.R.</given-names></name></person-group><article-title>Toxoplasma gondii infection in patients with psychiatric disorders from Western Romania</article-title><source>Medicina</source><volume>58</volume><issue>2</issue><year>2022</year><fpage>208</fpage><pub-id pub-id-type="doi">10.3390/medicina58020208</pub-id><pub-id pub-id-type="pmid">35208532</pub-id></element-citation></ref><ref id="bb0095"><element-citation publication-type="journal" id="rf202208230746289661"><person-group person-group-type="author"><name><surname>Guenter</surname><given-names>W.</given-names></name><name><surname>Bielinski</surname><given-names>M.</given-names></name><name><surname>Deptula</surname><given-names>A.</given-names></name><name><surname>Zalas-Wiecek</surname><given-names>P.</given-names></name><name><surname>Piskunowicz</surname><given-names>M.</given-names></name><name><surname>Szwed</surname><given-names>K.</given-names></name><name><surname>Borkowska</surname><given-names>A.</given-names></name><x>&#x02026;</x></person-group><article-title>Does Toxoplasma gondii infection affect cognitive function?A case control study</article-title><source>Folia Parasitol.</source><volume>59</volume><issue>2</issue><year>2012</year><fpage>93</fpage><lpage>98</lpage></element-citation></ref><ref id="bb0100"><element-citation publication-type="journal" id="rf202208230752553011"><person-group person-group-type="author"><name><surname>Harvey</surname><given-names>P.D.</given-names></name><name><surname>Strassnig</surname><given-names>M.T.</given-names></name><name><surname>Silberstein</surname><given-names>J.</given-names></name></person-group><article-title>Prediction of disability in schizophrenia: Symptoms, cognition, and self-assessment</article-title><source>J. Exp. Psychopathol.</source><volume>10</volume><issue>3</issue><year>2019</year><object-id pub-id-type="publisher-id">2043808719865693</object-id></element-citation></ref><ref id="bb0105"><element-citation publication-type="journal" id="rf202208230758492490"><person-group person-group-type="author"><name><surname>Jaeger</surname><given-names>J.</given-names></name></person-group><article-title>Digit symbol substitution test: the case for sensitivity over specificity in neuropsychological testing</article-title><source>J. Clin. Psychopharmacol.</source><volume>38</volume><issue>5</issue><year>2018</year><fpage>513</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1097/JCP.0000000000000941</pub-id><pub-id pub-id-type="pmid">30124583</pub-id></element-citation></ref><ref id="bb0110"><element-citation publication-type="journal" id="rf202208230800124519"><person-group person-group-type="author"><name><surname>Kannan</surname><given-names>G.</given-names></name><name><surname>Pletnikov</surname><given-names>M.V.</given-names></name></person-group><article-title>Toxoplasma gondii and cognitive deficits in schizophrenia: an animal model perspective</article-title><source>Schizophr. Bull.</source><volume>38</volume><issue>6</issue><year>2012</year><fpage>1155</fpage><lpage>1161</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbs079</pub-id><pub-id pub-id-type="pmid">22941742</pub-id></element-citation></ref><ref id="bb0115"><element-citation publication-type="book" id="rf202208230752041752"><person-group person-group-type="author"><name><surname>Keefe</surname><given-names>R.S.</given-names></name><name><surname>Harvey</surname><given-names>P.D.</given-names></name></person-group><part-title>Cognitive impairment in schizophrenia</part-title><source>Novel Antischizophrenia Treatments</source><year>2012</year><fpage>11</fpage><lpage>37</lpage></element-citation></ref><ref id="bb0120"><element-citation publication-type="journal" id="rf202208230800061829"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>M.S.</given-names></name><name><surname>Namgoong</surname><given-names>Y.</given-names></name><name><surname>Youn</surname><given-names>T.</given-names></name></person-group><article-title>Effect of organizational strategy on visual memory in patients with schizophrenia</article-title><source>Psychiatry Clin. Neurosci.</source><volume>62</volume><issue>4</issue><year>2008</year><fpage>427</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1819.2008.01821.x</pub-id><pub-id pub-id-type="pmid">18778440</pub-id></element-citation></ref><ref id="bb0125"><element-citation publication-type="journal" id="rf202208230754200250"><person-group person-group-type="author"><name><surname>Kozar</surname><given-names>Z.</given-names></name></person-group><article-title>Badania nad toksoplazmoza wsrod umyslowo chorych. Bull Inst Mar Trop Med Gdansk, 5, 146-173. Summary in English: Studies of toxoplasmosis among the mentally sick</article-title><source>Bull. Inst. Marit. Trop. Med. Gdansk</source><volume>1953</volume><issue>5</issue><year>1953</year><fpage>142</fpage><lpage>145</lpage></element-citation></ref><ref id="bb0130"><element-citation publication-type="journal" id="rf202208230800093069"><person-group person-group-type="author"><name><surname>Laere</surname><given-names>E.</given-names></name><name><surname>Tee</surname><given-names>S.F.</given-names></name><name><surname>Tang</surname><given-names>P.Y.</given-names></name></person-group><article-title>Assessment of cognition in schizophrenia using trail making test: a meta-analysis</article-title><source>Psychiatry Investig.</source><volume>15</volume><issue>10</issue><year>2018</year><fpage>945</fpage><lpage>955</lpage><pub-id pub-id-type="doi">10.30773/pi.2018.07.22</pub-id></element-citation></ref><ref id="bb0135"><element-citation publication-type="journal" id="rf202208230744525332"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>D.A.</given-names></name><name><surname>Levitt</surname><given-names>P.</given-names></name></person-group><article-title>Schizophrenia as a disorder of neurodevelopment annu</article-title><source>Rev. Neurosci.</source><volume>25</volume><year>2002</year><fpage>409</fpage><lpage>432</lpage></element-citation></ref><ref id="bb0140"><element-citation publication-type="journal" id="rf202208230756299223"><person-group person-group-type="author"><name><surname>Marenco</surname><given-names>S.</given-names></name><name><surname>Weinberger</surname><given-names>D.R.</given-names></name></person-group><article-title>The neurodevelopmental hypothesis of schizophrenia: following a trail of evidence from cradle to grave</article-title><source>Dev. Psychopathol.</source><volume>12</volume><issue>3</issue><year>2000</year><fpage>501</fpage><lpage>527</lpage><pub-id pub-id-type="pmid">11014750</pub-id></element-citation></ref><ref id="bb0145"><element-citation publication-type="journal" id="rf202208230757423181"><person-group person-group-type="author"><name><surname>Mendy</surname><given-names>A.</given-names></name><name><surname>Vieira</surname><given-names>E.R.</given-names></name><name><surname>Albatineh</surname><given-names>A.N.</given-names></name><name><surname>Gasana</surname><given-names>J.</given-names></name></person-group><article-title>Toxoplasma gondii seropositivity and cognitive functions in school-aged children</article-title><source>Parasitology</source><volume>142</volume><issue>9</issue><year>2015</year><fpage>1221</fpage><lpage>1227</lpage><pub-id pub-id-type="doi">10.1017/S0031182015000505</pub-id><comment>PMID: 2599062</comment><pub-id pub-id-type="pmid">25990628</pub-id></element-citation></ref><ref id="bb0150"><element-citation publication-type="journal" id="rf202208230757390601"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>C.L.</given-names></name><name><surname>Llenos</surname><given-names>I.C.</given-names></name><name><surname>Dulay</surname><given-names>J.R.</given-names></name><name><surname>Barillo</surname><given-names>M.M.</given-names></name><name><surname>Yolken</surname><given-names>R.H.</given-names></name><name><surname>Weis</surname><given-names>S.</given-names></name></person-group><article-title>Expression of the kynurenine pathway enzyme tryptophan 2, 3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia</article-title><source>Neurobiol. Dis.</source><volume>15</volume><issue>3</issue><year>2004</year><fpage>618</fpage><lpage>629</lpage><pub-id pub-id-type="pmid">15056470</pub-id></element-citation></ref><ref id="bb0155"><element-citation publication-type="journal" id="rf202208230758118511"><person-group person-group-type="author"><name><surname>Nimgaonkar</surname><given-names>V.L.</given-names></name><name><surname>Yolken</surname><given-names>R.H.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Chang</surname><given-names>C.C.H.</given-names></name><name><surname>McClain</surname><given-names>L.</given-names></name><name><surname>McDade</surname><given-names>E.</given-names></name><name><surname>Ganguli</surname><given-names>M.</given-names></name><x>&#x02026;</x></person-group><article-title>Temporal cognitive decline associated with exposure to infectious agents in a population-based, aging cohort</article-title><source>Alzheimer Dis. Assoc. Disord.</source><volume>30</volume><issue>3</issue><year>2016</year><fpage>216</fpage><pub-id pub-id-type="doi">10.1097/WAD.0000000000000133</pub-id><comment>PMID:26710257</comment><pub-id pub-id-type="pmid">26710257</pub-id></element-citation></ref><ref id="bb0160"><element-citation publication-type="journal" id="rf202208230800030049"><person-group person-group-type="author"><name><surname>Obayashi</surname><given-names>S.</given-names></name><name><surname>Matsushima</surname><given-names>E.</given-names></name><name><surname>Ando</surname><given-names>H.</given-names></name><name><surname>Ando</surname><given-names>K.</given-names></name><name><surname>Kojima</surname><given-names>T.</given-names></name></person-group><article-title>Exploratory eye movements during the Benton Visual Retention Test: characteristics of visual behavior in schizophrenia</article-title><source>Psychiatry Clin. Neurosci.</source><volume>57</volume><issue>4</issue><year>2003</year><fpage>409</fpage><lpage>415</lpage><pub-id pub-id-type="pmid">12839523</pub-id></element-citation></ref><ref id="bb0165"><element-citation publication-type="journal" id="rf202208230759385819"><person-group person-group-type="author"><name><surname>O'Leary</surname><given-names>D.S.</given-names></name><name><surname>Flaum</surname><given-names>M.</given-names></name><name><surname>Kesler</surname><given-names>M.L.</given-names></name><name><surname>Flashman</surname><given-names>L.A.</given-names></name><name><surname>Arndt</surname><given-names>S.</given-names></name><name><surname>Andreasen</surname><given-names>N.C.</given-names></name></person-group><article-title>Cognitive correlates of the negative, disorganized, and psychotic symptom dimensions of schizophrenia</article-title><source>J. Neuropsychiatry Clin. Neurosci.</source><volume>12</volume><issue>1</issue><year>2000</year><fpage>4</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">10678506</pub-id></element-citation></ref><ref id="bb0170"><element-citation publication-type="journal" id="rf202208230753404631"><person-group person-group-type="author"><name><surname>Ortiz-Guerrero</surname><given-names>G.</given-names></name><name><surname>Gonzalez-Reyes</surname><given-names>R.E.</given-names></name><name><surname>de-la-Torre</surname><given-names>A.</given-names></name><name><surname>Medina-Rinc&#x000f3;n</surname><given-names>G.</given-names></name><name><surname>Nava-Mesa</surname><given-names>M.O.</given-names></name></person-group><article-title>Pathophysiological mechanisms of cognitive impairment and neurodegeneration by Toxoplasma gondii infection</article-title><source>Brain Sci.</source><volume>10</volume><issue>6</issue><year>2020</year><fpage>369</fpage></element-citation></ref><ref id="bb0175"><element-citation publication-type="journal" id="rf202208230757541831"><person-group person-group-type="author"><name><surname>Pearce</surname><given-names>B.D.</given-names></name><name><surname>Kruszon-Moran</surname><given-names>D.</given-names></name><name><surname>Jones</surname><given-names>J.L.</given-names></name></person-group><article-title>The association of Toxoplasma gondii infection with neurocognitive deficits in a population-based analysis</article-title><source>Soc. Psychiatry Psychiatr. Epidemiol.</source><volume>49</volume><issue>6</issue><year>2014</year><fpage>1001</fpage><lpage>1010</lpage><pub-id pub-id-type="doi">10.1007/s00127-014-0820-5</pub-id><comment>PMID: 24477344</comment><pub-id pub-id-type="pmid">24477344</pub-id></element-citation></ref><ref id="bb0180"><element-citation publication-type="journal" id="rf202208230755025799"><person-group person-group-type="author"><name><surname>Pearce</surname><given-names>B.D.</given-names></name><name><surname>Massa</surname><given-names>N.</given-names></name><name><surname>Goldsmith</surname><given-names>D.R.</given-names></name><name><surname>Gandhi</surname><given-names>Z.H.</given-names></name><name><surname>Hankus</surname><given-names>A.</given-names></name><name><surname>Alrohaibani</surname><given-names>A.</given-names></name><name><surname>Duncan</surname><given-names>E.</given-names></name></person-group><article-title>Toxoplasma gondii effects on the relationship of kynurenine pathway metabolites to acoustic startle latency in schizophrenia vs. control subjects</article-title><source>Front. Psychiatry</source><volume>1246</volume><year>2020</year></element-citation></ref><ref id="bb0185"><element-citation publication-type="journal" id="rf202208230745432062"><person-group person-group-type="author"><name><surname>Pedraz-Petrozzi</surname><given-names>B.</given-names></name><name><surname>Elyamany</surname><given-names>O.</given-names></name><name><surname>Rummel</surname><given-names>C.</given-names></name><name><surname>Mulert</surname><given-names>C.</given-names></name></person-group><article-title>Effects of inflammation on the kynurenine pathway in schizophrenia&#x02014;a systematic review</article-title><source>J. Neuroinflammation</source><volume>17</volume><issue>1</issue><year>2020</year><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">31900165</pub-id></element-citation></ref><ref id="bb0190"><element-citation publication-type="journal" id="rf202208230744540642"><person-group person-group-type="author"><name><surname>Pettersson</surname><given-names>E.</given-names></name><name><surname>Lichtenstein</surname><given-names>P.</given-names></name><name><surname>Larsson</surname><given-names>H.</given-names></name><name><surname>Song</surname><given-names>J.</given-names></name><name><surname>Agrawal</surname><given-names>A.</given-names></name><name><surname>B&#x000f8;rglum</surname><given-names>A.</given-names></name><name><surname>Polderman</surname><given-names>T.</given-names></name></person-group><article-title>Genetic influences on eight psychiatric disorders based on family data of 4 408 646 full and half-siblings, and genetic data of 333 748 cases and controls</article-title><source>Psychol. Med.</source><volume>49</volume><issue>7</issue><year>2019</year><fpage>1166</fpage><lpage>1173</lpage><pub-id pub-id-type="doi">10.1017/S0033291718002039</pub-id><pub-id pub-id-type="pmid">30221610</pub-id></element-citation></ref><ref id="bb0195"><element-citation publication-type="journal" id="rf202208230745543521"><person-group person-group-type="author"><name><surname>Rossini</surname><given-names>J.C.</given-names></name><name><surname>Lopes</surname><given-names>C.S.</given-names></name><name><surname>Dirscherl</surname><given-names>F.P.</given-names></name><name><surname>Silva</surname><given-names>D.A.</given-names></name><name><surname>Mineo</surname><given-names>J.R.</given-names></name></person-group><article-title>Altered visual attention behavior of Toxoplasma gondii-infected individuals</article-title><source>Psychol. Neurosci.</source><volume>12</volume><issue>4</issue><year>2019</year><fpage>485</fpage></element-citation></ref><ref id="bb0200"><element-citation publication-type="journal" id="rf202208230757249882"><person-group person-group-type="author"><name><surname>Schwarcz</surname><given-names>R.</given-names></name><name><surname>Hunter</surname><given-names>C.A.</given-names></name></person-group><article-title>Toxoplasma gondii and schizophrenia: linkage through astrocyte-derived kynurenic acid?</article-title><source>Schizophr. Bull.</source><volume>33</volume><issue>3</issue><year>2007</year><fpage>652</fpage><lpage>653</lpage><pub-id pub-id-type="pmid">17434932</pub-id></element-citation></ref><ref id="bb0205"><element-citation publication-type="journal" id="rf202208230800236459"><person-group person-group-type="author"><name><surname>Singh-Manoux</surname><given-names>A.</given-names></name><name><surname>Marmot</surname><given-names>M.G.</given-names></name><name><surname>Glymour</surname><given-names>M.</given-names></name><name><surname>Sabia</surname><given-names>S.</given-names></name><name><surname>Kivim&#x000e4;ki</surname><given-names>M.</given-names></name><name><surname>Dugravot</surname><given-names>A.</given-names></name></person-group><article-title>Does cognitive reserve shape cognitive decline?</article-title><source>Ann. Neurol.</source><volume>70</volume><issue>2</issue><year>2011</year><fpage>296</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1002/ana.22391</pub-id><pub-id pub-id-type="pmid">21563209</pub-id></element-citation></ref><ref id="bb0210"><element-citation publication-type="journal" id="rf202208230759227270"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>T.W.</given-names></name></person-group><article-title>Neuropharmacology of quinolinic and kynurenic acids</article-title><source>Pharmacol. Rev.</source><volume>45</volume><issue>3</issue><year>1993</year><fpage>309</fpage><lpage>379</lpage><pub-id pub-id-type="pmid">8248282</pub-id></element-citation></ref><ref id="bb0215"><element-citation publication-type="journal" id="rf202208230746392581"><person-group person-group-type="author"><name><surname>Sugden</surname><given-names>K.</given-names></name><name><surname>Moffitt</surname><given-names>T.E.</given-names></name><name><surname>Pinto</surname><given-names>L.</given-names></name><name><surname>Poulton</surname><given-names>R.</given-names></name><name><surname>Williams</surname><given-names>B.S.</given-names></name><name><surname>Caspi</surname><given-names>A.</given-names></name></person-group><article-title>Is Toxoplasma gondii infection related to brain and behavior impairments in humans? Evidence from a population-representative birth cohort</article-title><source>PLoS One</source><volume>11</volume><issue>2</issue><year>2016</year><object-id pub-id-type="publisher-id">e014843</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0148435</pub-id><comment>PMID:26886853</comment></element-citation></ref><ref id="bb0220"><element-citation publication-type="journal" id="rf202208230758256761"><person-group person-group-type="author"><name><surname>Torniainen-Holm</surname><given-names>M.</given-names></name><name><surname>Suvisaari</surname><given-names>J.</given-names></name><name><surname>Lindgren</surname><given-names>M.</given-names></name><name><surname>H&#x000e4;rk&#x000e4;nen</surname><given-names>T.</given-names></name><name><surname>Dickerson</surname><given-names>F.</given-names></name><name><surname>Yolken</surname><given-names>R.H.</given-names></name></person-group><article-title>The lack of association between herpes simplex virus 1 or Toxoplasma gondii infection and cognitive decline in the general population: an 11-year follow-up study</article-title><source>Brain Behav. Immun.</source><volume>76</volume><year>2019</year><fpage>159</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2018.11.016</pub-id><comment>PMID: 30465879</comment><pub-id pub-id-type="pmid">30465879</pub-id></element-citation></ref><ref id="bb0225"><element-citation publication-type="journal" id="rf202208230759264370"><person-group person-group-type="author"><name><surname>Torrey</surname><given-names>E.F.</given-names></name><name><surname>Yolken</surname><given-names>R.H.</given-names></name></person-group><article-title>Toxoplasma gondii and schizophrenia</article-title><source>Emerg. Infect. Dis.</source><volume>9</volume><issue>11</issue><year>2003</year><fpage>1375</fpage><pub-id pub-id-type="pmid">14725265</pub-id></element-citation></ref><ref id="bb0230"><element-citation publication-type="journal" id="rf202208230757072772"><person-group person-group-type="author"><name><surname>Tutakhail</surname><given-names>A.</given-names></name><name><surname>Boulet</surname><given-names>L.</given-names></name><name><surname>Khabil</surname><given-names>S.</given-names></name><name><surname>Nazari</surname><given-names>Q.A.</given-names></name><name><surname>Hamid</surname><given-names>H.</given-names></name><name><surname>Coudor&#x000e9;</surname><given-names>F.</given-names></name></person-group><article-title>Neuropathology of kynurenine pathway of tryptophan metabolism</article-title><source>Curr. Pharmacol. Rep.</source><volume>6</volume><issue>1</issue><year>2020</year><fpage>8</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1007/s40495-019-00208-2</pub-id></element-citation></ref><ref id="bb0235"><element-citation publication-type="journal" id="rf202208230758454970"><person-group person-group-type="author"><name><surname>Veale</surname><given-names>J.F.</given-names></name></person-group><article-title>Edinburgh handedness inventory&#x02013;short form: a revised version based on confirmatory factor analysis</article-title><source>Laterality</source><volume>19</volume><issue>2</issue><year>2014</year><fpage>164</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1080/1357650X.2013.783045</pub-id><pub-id pub-id-type="pmid">23659650</pub-id></element-citation></ref><ref id="bb0240"><element-citation publication-type="journal" id="rf202208230756414353"><person-group person-group-type="author"><name><surname>Veleva</surname><given-names>I.I.</given-names></name><name><surname>Stoimenova</surname><given-names>M.J.</given-names></name><name><surname>Chumpalova</surname><given-names>P.G.</given-names></name><name><surname>Stoychev</surname><given-names>K.R.</given-names></name><name><surname>Tumbev</surname><given-names>L.Z.</given-names></name><name><surname>Valkova</surname><given-names>M.P.</given-names></name></person-group><article-title>Processing speed as an endophenotypic marker of paranoid schizophrenia</article-title><source>J.Biomed.Clin.Res.</source><volume>12</volume><issue>2</issue><year>2019</year><fpage>131</fpage><lpage>138</lpage></element-citation></ref><ref id="bb0245"><element-citation publication-type="journal" id="rf202208230759491529"><person-group person-group-type="author"><name><surname>Ventura</surname><given-names>J.</given-names></name><name><surname>Thames</surname><given-names>A.D.</given-names></name><name><surname>Wood</surname><given-names>R.C.</given-names></name><name><surname>Guzik</surname><given-names>L.H.</given-names></name><name><surname>Hellemann</surname><given-names>G.S.</given-names></name></person-group><article-title>Disorganization and reality distortion in schizophrenia: a meta-analysis of the relationship between positive symptoms and neurocognitive deficits</article-title><source>Schizophr. Res.</source><volume>121</volume><issue>1&#x02013;3</issue><year>2010</year><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2010.05.033</pub-id><pub-id pub-id-type="pmid">20579855</pub-id></element-citation></ref><ref id="bb0250"><element-citation publication-type="book" id="rf202208230747136161"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><part-title>International Statistical Classification of Diseases And Related Health Problems. - 10-th Revision</part-title><edition>Fifth edition</edition><year>2016</year></element-citation></ref><ref id="bb0255"><element-citation publication-type="book" id="rf202208230755371876"><person-group person-group-type="author"><collab>World Medical Association Declaration of Helsinki</collab></person-group><part-title>Ethical principles for medical research involving human subjects</part-title><source>Bulletin of the World Health Organization</source><year>2001</year><publisher-name>World Health Organization</publisher-name><fpage>373</fpage><lpage>374</lpage><comment>Available online at: https://apps.who.int/iris/handle/10665/268312 (accessed Oct 23, 2021)</comment></element-citation></ref><ref id="bb0260"><element-citation publication-type="journal" id="rf202208230744551592"><person-group person-group-type="author"><name><surname>Wray</surname><given-names>N.R.</given-names></name><name><surname>Gottesman</surname><given-names>I.I.</given-names></name></person-group><article-title>Using summary data from the Danish National Registers to estimate heritabilities for schizophrenia, bipolar disorder, and major depressive disorder</article-title><source>Front. Genet.</source><volume>3</volume><year>2012</year><fpage>118</fpage><pub-id pub-id-type="doi">10.3389/fgene.2012.00118</pub-id><pub-id pub-id-type="pmid">22783273</pub-id></element-citation></ref><ref id="bb0265"><element-citation publication-type="journal" id="rf202208230800157369"><person-group person-group-type="author"><name><surname>Zai</surname><given-names>G.</given-names></name><name><surname>Robbins</surname><given-names>T.W.</given-names></name><name><surname>Sahakian</surname><given-names>B.J.</given-names></name><name><surname>Kennedy</surname><given-names>J.L.</given-names></name></person-group><article-title>A review of molecular genetic studies of neurocognitive deficits in schizophrenia</article-title><source>Neurosci. Biobehav. Rev.</source><volume>72</volume><year>2017</year><fpage>50</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">27866942</pub-id></element-citation></ref></ref-list></back></article>
